Tirzepatide, sold under the brand name Mounjaro, is the newest injectable medication making waves in weight management. It works differently from semaglutide (Ozempic, Wegovy) and, in clinical trials, produced more weight loss than any medication before it. Mounjaro is now available in Canada, and patients in Edmonton are already using it. Here is what you need to know about how it works, what it costs, how it compares to semaglutide, and how to get it from your pharmacist.
What is tirzepatide?
Tirzepatide is a once-weekly injectable medication made by Eli Lilly. It belongs to a class called dual GIP/GLP-1 receptor agonists. That means it activates two gut hormone receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
Both of these hormones are released naturally after eating. They signal your brain to reduce appetite, slow stomach emptying so you feel full longer, and improve how your body handles blood sugar and insulin. By activating both receptors simultaneously, tirzepatide amplifies these effects beyond what a single-receptor drug can achieve.
In Canada, tirzepatide is marketed as Mounjaro for type 2 diabetes. In the United States, Eli Lilly also sells a weight-management-specific version called Zepbound. The molecule is the same, the difference is the approved indication and packaging.
How tirzepatide differs from semaglutide
If you have been reading about semaglutide for weight loss, you already know the basics of how GLP-1 medications work. Tirzepatide takes that approach further by adding a second mechanism.
Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) is a GLP-1 receptor agonist only. It activates one receptor. Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two receptors. The GIP component appears to contribute additional benefits to fat metabolism, energy expenditure, and appetite regulation that GLP-1 alone does not fully provide.
Think of it this way: semaglutide presses one button in the appetite-control system. Tirzepatide presses two. The clinical data shows that the second button matters.
Clinical results: the SURMOUNT trials
The evidence for tirzepatide's weight loss efficacy comes primarily from the SURMOUNT trial program, a series of large, rigorous clinical trials conducted by Eli Lilly.
The headline results from SURMOUNT-1 (published in the New England Journal of Medicine):
- At the highest dose (15 mg weekly), participants lost an average of 22.5 percent of their body weight over 72 weeks
- At the middle dose (10 mg), average weight loss was 21.4 percent
- At the lowest dose (5 mg), average weight loss was 16.0 percent
- More than one in three participants on the highest dose lost over 25 percent of their body weight
For context, semaglutide (Wegovy) at its highest dose produces about 15 percent body weight loss in clinical trials. That was already considered a breakthrough. Tirzepatide at 15 mg went meaningfully further, producing results closer to what was previously only achievable with bariatric surgery.
Beyond weight loss, tirzepatide also improved blood pressure, cholesterol, blood sugar, liver fat, and waist circumference. These are the metabolic improvements that reduce long-term risk of heart disease, stroke, and type 2 diabetes.
Health Canada approval status
Health Canada has approved tirzepatide under the brand name Mounjaro for the treatment of type 2 diabetes. This means it is available at Canadian pharmacies with a prescription.
The weight-management-specific indication, equivalent to what Eli Lilly markets as Zepbound in the United States, is currently under review by Health Canada. A decision is expected, but no date has been confirmed.
In the meantime, Canadian physicians and prescribing pharmacists can prescribe Mounjaro off-label for weight loss. Off-label prescribing is common, legal, and supported by the clinical trial evidence. Many patients across Canada are already using Mounjaro specifically for weight management.
How to get tirzepatide in Canada
Right now, the pathway to access tirzepatide in Canada is:
- Get a prescription. You need a prescription from a physician, nurse practitioner, or (in Alberta) a prescribing pharmacist. The prescription will be written for Mounjaro, since that is the approved brand in Canada.
- Start at the lowest dose. Tirzepatide is initiated at 2.5 mg weekly for four weeks, then increased to 5 mg. Further dose increases (to 7.5 mg, 10 mg, 12.5 mg, or 15 mg) happen in 2.5 mg steps every four weeks, based on tolerability and response.
- Fill at a pharmacy that stocks it. Not every pharmacy carries Mounjaro. At Acme Drug Mart, we keep it in stock and can prescribe it directly.
You do not need a specialist referral. In Alberta, you can walk into a pharmacy that offers pharmacist prescribing and get assessed on the spot.
Cost in Canada
Tirzepatide (Mounjaro) costs approximately $300 to $500 per month in Canada, depending on the dose and pharmacy.
Insurance coverage is currently limited:
- Private insurance. Most private plans do not yet cover tirzepatide for weight loss. Some plans will cover it if the prescription is for type 2 diabetes. Coverage policies are evolving as the medication becomes more established.
- Alberta Blue Cross and provincial coverage. Not currently listed on the Alberta Drug Benefit List for weight loss. Patients with type 2 diabetes may have coverage through specific plan categories.
- Manufacturer programs. Eli Lilly periodically offers savings programs for Mounjaro. Availability changes, so ask your pharmacist about current options.
We will check your insurance coverage before you fill. If tirzepatide is not covered, we can also discuss alternatives including semaglutide or generic semaglutide, which may have different coverage profiles.
Who is a candidate for tirzepatide?
The clinical criteria for tirzepatide for weight management are similar to other GLP-1 weight loss medications:
- BMI of 30 or greater (obesity), or
- BMI of 27 or greater with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease
Tirzepatide is not appropriate for everyone. It should not be used during pregnancy or breastfeeding. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use it. A history of pancreatitis requires careful consideration.
Your pharmacist will review your full medical history, current medications, and health goals during the assessment.
Side effects
The side effect profile of tirzepatide is similar to semaglutide and other GLP-1 medications. The most common side effects are gastrointestinal:
- Nausea: the most frequently reported side effect, affecting roughly 25 to 30 percent of patients. Usually mild to moderate.
- Diarrhea: typically early in treatment or after dose increases.
- Decreased appetite: this is part of how the medication works, but some patients find the appetite reduction more intense than expected initially.
- Constipation: less common than nausea but can occur.
- Vomiting: less common than nausea; more likely during dose escalation.
These side effects are most pronounced during the first few weeks at each new dose and typically improve as your body adjusts. The slow dose-escalation schedule (increasing by 2.5 mg every four weeks) is specifically designed to minimize GI side effects.
Serious side effects are rare but include pancreatitis, gallbladder problems, and allergic reactions. Your pharmacist will discuss warning signs to watch for.
Semaglutide vs tirzepatide: how they compare
Both medications are effective for weight loss, but there are meaningful differences. Here is how they stack up across the factors that matter most to patients:
Mechanism of action. Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both GIP and GLP-1 receptors. The dual mechanism is the primary reason tirzepatide produces greater weight loss in clinical trials.
Weight loss efficacy. In clinical trials, tirzepatide at the highest dose (15 mg) produced an average of 22.5 percent body weight loss. Semaglutide at its highest dose (2.4 mg Wegovy) produced approximately 15 percent. At their respective middle doses, the gap narrows but tirzepatide still leads.
Dosing. Both are once-weekly subcutaneous injections. Semaglutide uses a pre-filled pen (Ozempic or Wegovy). Tirzepatide uses a single-dose pre-filled pen (KwikPen). Both are self-administered at home.
Side effects. Very similar profiles. Both cause nausea, diarrhea, and constipation, primarily during dose escalation. Neither has clearly fewer side effects than the other in head-to-head comparisons.
Cost in Canada. Both are in a similar price range of $300 to $500 per month, though exact pricing depends on dose and pharmacy. Semaglutide has been available longer and may have broader insurance coverage. Generic semaglutide options, when available, can reduce cost further.
Availability. Semaglutide has been available in Canada longer and has more established supply chains. Tirzepatide (Mounjaro) is newer to the Canadian market. Both can experience intermittent supply shortages due to high demand.
Which should you choose? If maximum weight loss is the priority and cost is comparable, tirzepatide has the edge based on clinical trial data. If insurance covers one but not the other, that often becomes the deciding factor. If you have tried semaglutide and plateaued or had side effects, switching to tirzepatide is a reasonable next step. Your pharmacist can help you weigh these factors based on your specific situation.
Getting tirzepatide in Edmonton
At Acme Drug Mart, we offer pharmacist prescribing for weight loss medications including tirzepatide. Here is what the process looks like:
- Walk in or call ahead. No doctor referral is required. Alberta pharmacists have the authority to assess and prescribe.
- Assessment. We review your BMI, medical history, current medications, previous weight loss attempts, and health goals.
- Medication selection. Based on your assessment, we discuss whether tirzepatide, semaglutide, or another option is the best fit. We check your insurance coverage for each option.
- Prescription and dispensing. If tirzepatide is appropriate, we prescribe and dispense it the same day. We teach you how to use the injection pen and set up your dose-escalation schedule.
- Follow-up. We monitor your progress, manage side effects, and adjust the dose as needed.
Call (780) 443-0202 or stop by during regular hours. We stock Mounjaro and can get you started without a wait.